Pandemic-Based Approach to Methadone Treatment Restrictions Should Remain, Study Finds

When the COVID-19 pandemic tore through the United States in early 2020, substance use disorder treatment centers were forced to make massive changes to minimize the spread of coronavirus.

The fear of COVID-19 spread into crowded treatment programs run by the national Substance Abuse and Mental Health Services Administration, prompting them to relax stringent federal regulations on distributing methadone, a common treatment for opioid use. The agency allowed programs to increase the number of take-home methadone doses that patients could receive and reduce the frequency of counseling and drug testing — changes that sparked concerns over medication diversion and lapses in treatment.

But a new study by researchers at the Yale School of Public Health finds that these concerns appear unfounded. Relaxing the requirements for dispensing take-home methadone treatments did not significantly lead to an increase in fatal methadone-related overdoses in Connecticut at all, they found. The changes also did not result in reductions in the number of patients receiving treatment for their opioid use disorder.

Read more:

You May Also Like…

Working from Home and Alcohol Use

Working from Home and Alcohol Use

This study examined the associations between working at home and alcohol consumption. Using data from a pre-COVID-19...


Submit a Comment

Your email address will not be published. Required fields are marked *